Medical Excellence Capital, an early-stage life sciences venture fund, led a $15m series A funding round in ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis and other debilitating brain diseases. "We are focused on accelerating the development of prosetin to meet the critical need for new treatments for people living with ALS. We are encouraged by the therapeutic window emerging from our phase 1 trial and ongoing nonclinical studies and are looking forward to advancing prosetin to people living with ALS in early 2024. We are also thrilled to welcome Rick to our board and know that he will add tremendous value given his extensive global commercial and business development experience at Merck," Stan Abel, ProJenX President and CEO.